Terms of Use | Privacy Policy
Abcentra's pharmaceutical products are investigational and not FDA approved
© 2019 Abcentra. All Rights Reserved.
Media
- All
- Mentions
- Press Releases
January 8, 2020
Article written by Allie Nawrat for Pharmaceutical Technology. Although there are evidence-based links between CVD and inflammatory conditions, and associated strong risk factors, they are often ignored when treating patients with either type of condition. Abcentra former CEO and current senior advisor Bert Liang wants to break through the physician and treatment siloes and develop... Read more »
December 20, 2019
Foundation Recognized for its Efforts to Prevent Premature Cardiovascular Disease due to High Lipoprotein(a), Reaching more than 110,000 People per Year in more than 160 Countries SAN CARLOS, Calif. — The Lipoprotein(a) Foundation was recently named a Top Nonprofit of 2019 by GreatNonprofits, the leading platform for community-sourced stories about nonprofits. The Foundation received... Read more »
December 13, 2019
Clinical-stage biopharmaceutical company completes clinical batch manufacturing in advance of upcoming psoriasis trial LOS ANGELES (December 13, 2019) – Abcentra LLC, a clinical-stage biopharmaceutical company developing first-in-class antibody therapeutics for inflammatory diseases, announced today the manufacturing completion of a clinical batch of drug substance for the company’s lead candidate, Orticumab, in advance of Abcentra’s upcoming... Read more »
October 16, 2019
by Matthew Pillar, Editor, BioProcess Online Bert Liang, M.D., Ph.D., stepped into the CEO role at Abcentra earlier this year as the company formerly known as CardioVax found itself at a crossroads. The company bills itself as a clinical-stage bio-pharma company that addresses unmet needs in inflammation by targeting oxidized low-density lipoprotein (oxLDL). When Liang stepped in,… Read more »
October 16, 2019
San Diego, CA (September 17, 2019) — Abcentra, a clinical-stage bio-pharmaceutical company that addresses unmet needs in inflammation, today announced its contribution to a 2019 study published in the American Heart Association Journals. The study found that, in ApoE/MHCII double knockout mice with high-cholesterol and major histocompatibility complex class II (MHCII) deficiency —atherosclerosis was increased… Read more »
October 16, 2019
LOS ANGELES, Jan. 30, 2019 /PRNewswire/ — CardioVax, a privately held, clinical-stage biopharmaceutical company developing novel antibody therapeutics for inflammatory diseases, announced today that it has changed its name to Abcentra. The company targets oxidized low-density lipoprotein (oxLDL) and its associated protein, apolipoproteinB-100 (apoB-100), as a key mediator of inflammation. The company’s new name, Abcentra is an acronym… Read more »
